ALIF_B: Strong sales, margin gains, and cash flow set the stage for robust growth in 2025

About this update from Addlife Ab Class B

Q4 2024 saw 11% sales growth, margin expansion, and strong cash flow, with both Labtech and Medtech segments performing well. Debt reduction and improved working capital position AddLife for a confident 2025 outlook. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Addlife Ab Class B